Cardiol Therapeutics Inc-a (CRDL) — 13F Holders Deep Dive (Q2 2026)

CRDL ranks #6018 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CRDL is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

53 institutions disclose a position in CRDL, but none treat it as a major bet — even Tejara Capital Ltd, its most concentrated holder, allocates just 2.2% of its own portfolio to it.

Two Sigma Investments, LP has added to its CRDL position for two straight quarters, increasing it by $403.6K to reach $791.8K today.

Susquehanna International Group, LLP has trimmed its CRDL position for two straight quarters, cutting it by $167.0K while still holding $27.3K.

CRDL is up 0.9% today, and institutions have been net buyers of $1.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRDL reported a net loss of $28.1M in its latest fiscal year.

• Not yet profitable — net loss of $28.1M in the latest fiscal year
• Net income improved year over year, from -$30.9M to -$28.1M
• Operating cash flow was negative, using $25.2M in cash
• Current ratio of 4.36x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.30x equity — within a conventional range